Cognitive impairment is a core symptom domain of schizophrenia. The effect of
antipsychotics, the cornerstone of treatment in schizophrenia, on this domain is not fully …

Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …

Drug discovery is at a near standstill for treating psychiatric disorders such as schizophrenia,
bipolar disorder, depression, and common forms of autism. Despite high prevalence and …

The aim of the present review was to systematically summarise our current understanding of
the structure of the cognitive heterogeneity that exists within schizophrenia spectrum …

The dopamine hypothesis has been the cornerstone in the research and clinical practice of
schizophrenia. With the initial emphasis on the role of excessive dopamine, the hypothesis …

Schizophrenia is characterized by positive, negative and cognitive symptoms. All current
antipsychotic treatments feature dopamine-receptor antagonism that is relatively effective at …

Introduction Nearly every individual with schizophrenia is affected by cognitive decline. The
aim of this literature review was to:(a) describe the humanistic burden of cognitive …

Background In many countries of the industrialised world second generation ('atypical')
antipsychotics have become the first line drug treatment for people with schizophrenia. The …

Disturbances in sustained attention commonly interfere with the ability of persons with
schizophrenia to benefit from evidence-based psychosocial treatments. Cognitive …

This chapter presents an updated review of the history, pharmacology, uses, efficacy, and
side effects of antipsychotic drugs (APDs) on the basis of currently available evidence. It …